LABORATOIRES EUROMEDIS(EPA:ALEMG) stock Fundamental Analysis

Fundamental Rating

ALEMG gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 53 industry peers in the Health Care Equipment & Supplies industry. ALEMG has an average financial health and profitability rating. ALEMG has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALEMG was profitable.

In multiple years ALEMG reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: ALEMG reported negative operating cash flow in multiple years.

1.2 Ratios

ALEMG has a Return On Assets of 27.66%. This is amongst the best in the industry. ALEMG outperforms 98.11% of its industry peers.

With an excellent Return On Equity value of 57.02%, ALEMG belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	27.66%
ROE	57.02%
ROIC	N/A

ROA(3y)7.18%

ROA(5y)7.85%

ROE(3y)15.48%

ROE(5y)16.44%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 24.05%, ALEMG belongs to the top of the industry, outperforming 92.45% of the companies in the same industry.

ALEMG's Profit Margin has improved in the last couple of years.

ALEMG has a Gross Margin of 31.89%. This is in the lower half of the industry: ALEMG underperforms 77.36% of its industry peers.

ALEMG's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	24.05%
GM	31.89%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y48.68%

PM growth 5YN/A

GM growth 3Y-2.88%

GM growth 5Y-2.61%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALEMG does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ALEMG has less shares outstanding

Compared to 5 years ago, ALEMG has less shares outstanding

ALEMG has a better debt/assets ratio than last year.

2.2 Solvency

ALEMG has an Altman-Z score of 1.67. This is a bad value and indicates that ALEMG is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of 1.67, ALEMG perfoms like the industry average, outperforming 54.72% of the companies in the same industry.

A Debt/Equity ratio of 0.41 indicates that ALEMG is not too dependend on debt financing.

With a Debt to Equity ratio value of 0.41, ALEMG perfoms like the industry average, outperforming 54.72% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	N/A
Altman-Z	1.67

ROIC/WACCN/A

WACC6.57%

2.3 Liquidity

A Current Ratio of 3.47 indicates that ALEMG has no problem at all paying its short term obligations.

ALEMG's Current ratio of 3.47 is amongst the best of the industry. ALEMG outperforms 81.13% of its industry peers.

A Quick Ratio of 2.57 indicates that ALEMG has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 2.57, ALEMG belongs to the top of the industry, outperforming 86.79% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.47
Quick Ratio	2.57

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 339.63% over the past year.

The earnings per share for ALEMG have been decreasing by -15.45% on average. This is quite bad

ALEMG shows a small growth in Revenue. In the last year, the Revenue has grown by 5.58%.

ALEMG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.58% yearly.

EPS 1Y (TTM)339.63%

EPS 3Y-15.45%

EPS 5YN/A

EPS Q2Q%89.97%

Revenue 1Y (TTM)5.58%

Revenue growth 3Y-43.96%

Revenue growth 5Y-20.58%

Sales Q2Q%-26.01%

3.2 Future

The Earnings Per Share is expected to grow by 22.41% on average over the next years. This is a very strong growth

The Revenue is expected to decrease by -11.48% on average over the next years. This is quite bad

EPS Next Y60%

EPS Next 2Y31.67%

EPS Next 3Y22.41%

EPS Next 5YN/A

Revenue Next Year5.19%

Revenue Next 2Y6.36%

Revenue Next 3Y-11.48%

Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.88, which indicates a rather cheap valuation of ALEMG.

100.00% of the companies in the same industry are more expensive than ALEMG, based on the Price/Earnings ratio.

The average S&P500 Price/Earnings ratio is at 24.21. ALEMG is valued rather cheaply when compared to this.

The Price/Forward Earnings ratio is 8.76, which indicates a very decent valuation of ALEMG.

Based on the Price/Forward Earnings ratio, ALEMG is valued cheaper than 90.57% of the companies in the same industry.

The average S&P500 Price/Forward Earnings ratio is at 20.44. ALEMG is valued rather cheaply when compared to this.

		Industry Rank	Sector Rank
PE	0.88
Fwd PE	8.76

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as ALEMG's earnings are expected to grow with 22.41% in the coming years.

PEG (NY)0.01

PEG (5Y)N/A

EPS Next 2Y31.67%

EPS Next 3Y22.41%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALEMG does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LABORATOIRES EUROMEDIS

EPA:ALEMG (5/9/2025, 7:00:00 PM)

3.91

+0.03 (+0.77%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)04-24 2025-04-24/amc

Earnings (Next)10-27 2025-10-27

Inst Owners4.63%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap11.22M

Analysts37.14

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	0.88
Fwd PE	8.76
P/S	0.21
P/FCF	N/A
P/OCF	N/A
P/B	0.51
P/tB	0.51
EV/EBITDA	N/A

EPS(TTM)4.42

EY113.04%

EPS(NY)0.45

Fwd EY11.42%

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS18.22

BVpS7.69

TBVpS7.68

PEG (NY)0.01

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	27.66%
ROE	57.02%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	24.05%
GM	31.89%
FCFM	N/A

ROA(3y)7.18%

ROA(5y)7.85%

ROE(3y)15.48%

ROE(5y)16.44%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y48.68%

PM growth 5YN/A

GM growth 3Y-2.88%

GM growth 5Y-2.61%

F-ScoreN/A

Asset Turnover1.15

Health

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.47
Quick Ratio	2.57
Altman-Z	1.67

F-ScoreN/A

WACC6.57%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)339.63%

EPS 3Y-15.45%

EPS 5YN/A

EPS Q2Q%89.97%

EPS Next Y60%

EPS Next 2Y31.67%

EPS Next 3Y22.41%

EPS Next 5YN/A

Revenue 1Y (TTM)5.58%

Revenue growth 3Y-43.96%

Revenue growth 5Y-20.58%

Sales Q2Q%-26.01%

Revenue Next Year5.19%

Revenue Next 2Y6.36%

Revenue Next 3Y-11.48%

Revenue Next 5YN/A

EBIT growth 1Y-86.02%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year163.64%

EBIT Next 3Y20.09%

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

LABORATOIRES EUROMEDIS (ALEMG.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens